Evrys Bio
Evrys Bio is a biotechnology company dedicated to developing broad-spectrum antiviral therapies that target human proteins called sirtuins. Their innovative approach enhances the body's natural ability to fight viral infections, addressing many viruses simultaneously and reducing the risk of drug resistance. The company aims to transform infectious disease treatment and explores applications in oncology and other chronic diseases. They are actively involved in research and development of host-targeted antiviral drugs, with a focus on viruses such as EBV, hepatitis B, influenza, SARS-CoV-2, Zika, and Cytomegalovirus. Evrys Bio collaborates with major organizations and has received significant funding to accelerate their efforts in creating effective treatments for viral infections and pandemics.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Pan-respiratory broad-spectrum antiviral candidate
A host-directed small-molecule antiviral program targeting sirtuin biology with in vitro activity against multiple respiratory viruses, intended for treatment of respiratory infections across multiple viral etiologies.
Opportunistic infections antiviral program (immunosuppressed patients)
An oral small-molecule antiviral development program intended to prevent or treat multiple opportunistic viral infections in immunocompromised patients, including herpesviruses and polyomaviruses.
Medical countermeasure / pandemic preparedness antiviral
A program targeting broad-spectrum activity against emerging and high-consequence pathogens for use as a rapid-response therapeutic and for stockpiling as a medical countermeasure.
Liver-targeted antiviral program (hepatotropic viruses)
Development of sirtuin-targeted antivirals optimized for liver indications with activity against agents that cause viral hepatitis and related hepatotropic infections.
Pan-respiratory broad-spectrum antiviral candidate
A host-directed small-molecule antiviral program targeting sirtuin biology with in vitro activity against multiple respiratory viruses, intended for treatment of respiratory infections across multiple viral etiologies.
Opportunistic infections antiviral program (immunosuppressed patients)
An oral small-molecule antiviral development program intended to prevent or treat multiple opportunistic viral infections in immunocompromised patients, including herpesviruses and polyomaviruses.
Medical countermeasure / pandemic preparedness antiviral
A program targeting broad-spectrum activity against emerging and high-consequence pathogens for use as a rapid-response therapeutic and for stockpiling as a medical countermeasure.
Liver-targeted antiviral program (hepatotropic viruses)
Development of sirtuin-targeted antivirals optimized for liver indications with activity against agents that cause viral hepatitis and related hepatotropic infections.
Services
Collaborations with external partners to support preclinical development, translational studies, and commercialization of host-directed antiviral programs.
Publication of peer-reviewed results and presentation of scientific updates at industry conferences to support external evaluation and partnering.
Partnerships with government agencies to execute funded programs for development of broad-spectrum therapeutics and medical countermeasures, including contract delivery and stockpile-readiness planning.
Collaborations with external partners to support preclinical development, translational studies, and commercialization of host-directed antiviral programs.
Publication of peer-reviewed results and presentation of scientific updates at industry conferences to support external evaluation and partnering.
Partnerships with government agencies to execute funded programs for development of broad-spectrum therapeutics and medical countermeasures, including contract delivery and stockpile-readiness planning.
Expertise Areas
- Antiviral drug discovery
- Host-directed therapeutics targeting sirtuins
- Preclinical virology and translational research
- Structure-guided small-molecule design
Key Technologies
- Host-directed antiviral approaches targeting sirtuin enzymes
- Computer-aided drug design (CADD)
- Structure-based design and X-ray crystallography
- Enzymatic inhibition assays (IC50 determination)